TRPV1 and Hyperoxaluria: Chronic delivery of two specific TRPV1 blockers, Capz and SB, for 7 and 14 days via subcutaneous mini-osmotic pump significantly attenuated hyperoxaluria-induced renal hypertrophy (as the ratio of kidney to body weight) (Figure 7).